Key result
DANWARD trial compares VKAs versus no anticoagulation for stroke and bleeding in AFib on dialysis.
Why the study?
It is unclear whether oral anticoagulation for stroke prevention is beneficial in patients with atrial fibrillation on chronic dialysis, as its potential benefit remains untested in randomized clinical trials comparing anticoagulation with no treatment.
Does standard dose VKA targeting an INR of 2.0-3.0 reduce stroke or transient ischaemic attack in patients with atrial fibrillation on chronic dialysis?
RCT (n=718)
Open-label
1:1
Yes
Does standard dose VKA targeting an INR of 2.0-3.0 reduce stroke or transient ischaemic attack in patients with atrial fibrillation on chronic dialysis?
The DANWARD trial protocol outlines an open-label RCT to determine if VKA therapy is safe and effective for stroke prevention in patients with atrial fibrillation on chronic dialysis compared to no oral anticoagulation.
Answers are grounded in this paper and cite their sources.
Optimal anticoagulation in dialysis AF remains uncertain; DANWARD RCT will deliver first randomized data on VKA stroke prevention versus bleeding.
INTRODUCTION: Atrial fibrillation is highly prevalent in patients on chronic dialysis. It is unclear whether anticoagulant therapy for stroke prevention is beneficial in these patients. Vitamin K-antagonists (VKA) remain the predominant anticoagulant choice. Importantly, anticoagulation remains inconsistently used and a possible benefit remains untested in randomised clinical trials comparing oral anticoagulation with no treatment in patients on chronic dialysis. The Danish Warfarin-Dialysis (DANWARD) trial aims to investigate the safety and efficacy of VKAs in patients with atrial fibrillation on chronic dialysis. The hypothesis is that VKA treatment compared with no treatment is associated with stroke risk reduction and overall benefit. METHODS AND ANALYSIS: The DANWARD trial is an investigator-initiated trial at 13 Danish dialysis centres. In an open-label randomised clinical trial study design, a total of 718 patients with atrial fibrillation on chronic dialysis will be randomised in a 1:1 ratio to receive either standard dose VKA targeting an international normalised ratio of 2.0-3.0 or no oral anticoagulation. Principal analyses will compare the risk of a primary efficacy endpoint, stroke or transient ischaemic attack and a primary safety endpoint, major bleeding, in patients allocated to VKA treatment and no treatment, respectively. The first patient was randomised in October 2019. Patients will be followed until 1 year after the inclusion of the last patient. ETHICS AND DISSEMINATION: The study protocol was approved by the Regional Research Ethics Committee (journal number H-18050839) and the Danish Medicines Agency (case number 2018101877). The trial is conducted in accordance with the Helsinki declaration and standards of Good Clinical Practice. Study results will be disseminated to participating sites, at research conferences and in peer-reviewed journals. TRIAL REGISTRATION NUMBERS: NCT03862859, EUDRA-CT 2018-000484-86 and CTIS ID 2022-502500-75-00.
No takes yet. Share an insight, caveat, or question.
Ballegaard et al. (2024) conducted an RCT in Atrial fibrillation on chronic dialysis (n=718). Vitamin K-antagonists (VKA) vs. No oral anticoagulation was evaluated on Stroke or transient ischaemic attack (efficacy) and major bleeding (safety). The DANWARD trial will randomize 718 patients with atrial fibrillation on chronic dialysis to vitamin K-antagonists or no oral anticoagulation to evaluate the risk of stroke, TIA, and major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: